Clinical Trial Update: Safety, Tolerability and PK Study of AK0529 in Healthy Human [Phase 1]

View source ↗

Summary

Phase 1 safety, tolerability, and pharmacokinetics study of AK0529 in healthy volunteers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• AK0529 (AK0529)

Snippet

Sponsor: Shanghai Ark Biopharmaceutical Co., Ltd. | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED